Healthcare Equipment and Supplies
Company Overview of Metamark Genetics, Inc.
Metamark Genetics, Inc. develops diagnostic and prognostic tests for urology cancer care. It offers ProMark, a protein based prognostic test for prostate cancer; and Progensa, a urine-based molecular test to make informed repeat biopsy decisions. The company also provides cytology diagnostic services for diagnosis of bladder cancer; luorescence in situ hybridization, a diagnostic tool that helps to confirm patient’s cytology results; histology diagnostic services for prostate and bladder biopsy analysis and examinations; and PTEN/ERG molecular testing that predicts aggressiveness of HGPIN/atypical or low gleason score. It offers services in the areas of diagnosis and management of prostate c...
245 First Street
Cambridge, MA 02142
Founded in 2007
Key Executives for Metamark Genetics, Inc.
Co-Founder, Chairman, Chief Executive Officer and President
Co-Founder, Director and Scientific & Clinical Advisor
Co-Founder and Scientific & Clinical Advisor
Chief Science Officer and Senior Vice President
Compensation as of Fiscal Year 2015.
Metamark Genetics, Inc. Key Developments
Metamark Genetics Names Peter Maimonis as Senior Vice President and Chief Science Officer
Oct 8 15
Metamark Genetics, Inc. announced that Peter Maimonis, Ph.D., has joined Metamark's leadership team as Senior Vice President and Chief Science Officer, effective October 7, 2015. Dr. Maimonis brings extensive experience in oncology research and development, and specific proficiency in oncology biomarkers in the area of prostate cancer. He has presented at a large number of national and international scientific conferences, and published many peer-reviewed articles and abstracts on cancer biomarkers. Dr. Maimonis has held senior level positions in various areas of research and development at Ciba-Corning, Chiron Diagnostics, Bayer Diagnostics, Decision Biomarkers, and On-Q-ity, and most recently served as Vice President of Biomarker Development at Biothera, working with their novel cancer immunotherapeutic.
Metamark Genetics, Inc Announces Management Changes
Sep 10 15
Metamark Genetics, Inc. announced that Kenneth E. Weg has been named as the company's new President and Chief Executive Officer, and continues as Chairman of the Board of Directors of Metamark. Mr. Weg succeeds Shawn Marcell, who resigned from his position to pursue other activities. Mr. Weg has more than thirty years of experience and previously served as the President of the Worldwide Medicines Group at Bristol-Myers Squibb (BMS).
Metamark Appoints Jerome Richie as Chief Medical Officer, Effective July 1, 2015
Jun 23 15
Metamark has appointed Dr. Jerome Richie as its chief medical officer. Richie will join the leadership team effective July 1, retiring from his current role of chief emeritus of Harvard program in Urology at Brigham and Women's Hospital and a surgery professor at Harvard Medical School.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 10, 2015